| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1996PNAS...93.7196S |
| P356 | DOI | 10.1073/PNAS.93.14.7196 |
| P932 | PMC publication ID | 38959 |
| P698 | PubMed publication ID | 8692968 |
| P5875 | ResearchGate publication ID | 14509225 |
| P50 | author | Jan Holmgren | Q5811529 |
| P2093 | author name string | Olsson T | |
| Sun JB | |||
| Rask C | |||
| Czerkinsky C | |||
| P2860 | cites work | Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones | Q29622840 |
| Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development | Q33831194 | ||
| Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory | Q34225394 | ||
| Specific T-cell tolerance may reflect selective activation of lymphokine synthesis | Q34581164 | ||
| Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis | Q34719541 | ||
| Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues | Q35093806 | ||
| Susceptibility to experimental allergic encephalomyelitis in animal models of autoimmunity | Q35325981 | ||
| Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. | Q35591418 | ||
| Vaccine-specific T cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine | Q35774856 | ||
| Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance | Q35878983 | ||
| Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents | Q36410653 | ||
| Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen | Q37401915 | ||
| Could specific oral tolerance be a therapy for autoimmune disease? | Q37783108 | ||
| Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens | Q40661200 | ||
| T cell growth factor: parameters of production and a quantitative microassay for activity | Q40680131 | ||
| Inhibition of specific immune responses by feeding protein antigens. II. Effects of prior passive and active immunization | Q41633022 | ||
| Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen | Q41742673 | ||
| Gamma-interferon-induced activation of latent transforming growth factor-beta by human monocytes | Q41754784 | ||
| Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen | Q44466252 | ||
| Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats | Q44815781 | ||
| Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. | Q44874730 | ||
| Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species | Q46193929 | ||
| Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein | Q46690191 | ||
| Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse | Q48532989 | ||
| Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1 | Q48655440 | ||
| The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis | Q53438445 | ||
| Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells | Q57352286 | ||
| Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1 | Q67687123 | ||
| Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats | Q68350420 | ||
| Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments | Q69013296 | ||
| Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma | Q70379216 | ||
| Lymphocyte recruitment in delayed-type hypersensitivity. The role of IFN-gamma | Q70385935 | ||
| Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor | Q70745453 | ||
| Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines | Q72271829 | ||
| The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones | Q72709525 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholera | Q12090 |
| experimental autoimmune encephalomyelitis | Q494066 | ||
| P304 | page(s) | 7196-7201 | |
| P577 | publication date | 1996-07-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit | |
| P478 | volume | 93 |
| Q36140954 | A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes |
| Q50126055 | A cloning vector for efficient generation of cholera toxin B gene fusions for epitope screening |
| Q63370226 | A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection |
| Q27633142 | A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity |
| Q45889680 | A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes |
| Q93024677 | A review on edible vaccines and their prospects |
| Q35586474 | Activation and suppression of the proinflammatory immune response by Vibrio cholerae toxins |
| Q35134310 | Active immunization using a single dose immunotherapeutic abates established EAE via IL-10 and regulatory T cells |
| Q37001778 | Anti-inflammatory effect of cholera toxin B subunit in experimental stroke |
| Q38353887 | Assembly of cholera toxin B subunit full-length rotavirus NSP4 fusion protein oligomers in transgenic potato |
| Q34113929 | Autoantigens plus interleukin-10 suppress diabetes autoimmunity |
| Q39522002 | Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells |
| Q36551840 | Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function. |
| Q39971245 | Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation |
| Q39849692 | Cholera toxin B subunit-domain III of dengue virus envelope glycoprotein E fusion protein production in transgenic plants |
| Q40813264 | Cholera toxin and Escherichia coli enterotoxin B-subunits inhibit macrophage-mediated antigen processing and presentation: evidence for antigen persistence in non-acidic recycling endosomal compartments |
| Q39741614 | Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development |
| Q24598726 | Cholera toxin: a paradigm of a multifunctional protein |
| Q35098194 | Comparative proteomic analysis reveals activation of mucosal innate immune signaling pathways during cholera |
| Q36640326 | Delivery systems and adjuvants for oral vaccines. |
| Q52025414 | Differential effect of cholera toxin on CD45RA+ and CD45RO+ T cells: specific inhibition of cytokine production but not proliferation of human naive T cells. |
| Q35619878 | Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent |
| Q74401546 | Efficacy of a food plant-based oral cholera toxin B subunit vaccine |
| Q46342747 | Efficient induction of oral tolerance by fusing cholera toxin B subunit with allergen-specific T-cell epitopes accumulated in rice seed |
| Q54150448 | Expression of cholera toxin B subunit oligomers in transgenic potato plants. |
| Q41947780 | Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts |
| Q54544388 | Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo. |
| Q37749719 | Heat-labile enterotoxins as adjuvants or anti-inflammatory agents |
| Q45744003 | Humoral immunoresponse to varicella-zoster virus pernasally coadministered with Escherichia coli enterotoxin in mice |
| Q33525565 | IL-28 supplants requirement for T(reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE) |
| Q38971911 | Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease |
| Q34102006 | Immune modulation by the cholera-like enterotoxin B-subunits: from adjuvant to immunotherapeutic |
| Q33546865 | Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic |
| Q34933032 | Immune response induced by recombinant Mycobacterium bovis BCG producing the cholera toxin B subunit. |
| Q36055986 | Immune response versus mucosal tolerance to mucosally administered antigens |
| Q35753555 | Immunomodulation and vaccination for atherosclerosis |
| Q34184898 | Immunomodulation using bacterial enterotoxins |
| Q36320323 | Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections |
| Q37682917 | Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. |
| Q28770045 | Induction of thymus-derived gammadelta T Cells by Escherichia coli enterotoxin b subunit in peritoneal cavities of mice |
| Q33769366 | Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue |
| Q43581512 | Long-term persistence of cellular immunity to Oka vaccine virus induced by pernasal co-administration with Escherichia coli enterotoxin in mice |
| Q37069755 | Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. |
| Q36743545 | MAPK phosphatases--regulating the immune response |
| Q34008642 | Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance |
| Q73933686 | Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens |
| Q54542514 | Modulation of human monocytes by Escherichia coli heat-labile enterotoxin B-subunit; altered cytokine production and its functional consequences. |
| Q42854644 | Modulation of systemic antigen-specific immune responses by oral antigen in humans. |
| Q47827263 | Molecular and antigenic structure of nicotinic acetylcholine receptors. |
| Q48003593 | Molecular basis of type II collagen autoimmune ear diseases |
| Q33776172 | Mucosal immunity and tolerance: relevance to vaccine development |
| Q34409172 | Mucosal immunity and vaccines |
| Q34715639 | Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functions |
| Q74541097 | Nasal administration of cholera toxin (CT) suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE) |
| Q43683297 | Oral administration of collagen conjugated with cholera toxin induces tolerance to type II collagen and suppresses chondritis in an animal model of autoimmune ear disease |
| Q74220407 | Oral tolerance |
| Q34998321 | Oral tolerance for treating uveitis - new hope for an old immunological mechanism |
| Q43040918 | Oral tolerance in disease |
| Q73779689 | Oral tolerance in experimental autoimmune neuritis (EAN) of the Lewis rat. II. Adjuvant effects and bystander suppression in P2 peptide-induced EAN |
| Q79859166 | Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells |
| Q24548763 | Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection |
| Q36090197 | Peptide-based therapeutic vaccines for allergic and autoimmune diseases |
| Q37776723 | Plant-made pharmaceuticals for the prevention and treatment of autoimmune diseases: where are we? |
| Q50117900 | Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization |
| Q36771712 | Prevention of autoimmune disease due to lymphocyte modulation by the B-subunit of Escherichia coli heat-labile enterotoxin |
| Q73882350 | Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis |
| Q54471977 | Protection of non-obese diabetic mice from autoimmune diabetes by Escherichia coli heat-labile enterotoxin B subunit. |
| Q73443851 | Purified cholera toxin B subunit from transgenic tobacco plants possesses authentic antigenicity |
| Q34407903 | Rotavirus NSP4: a multifunctional viral enterotoxin |
| Q33928456 | Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine |
| Q52681524 | Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells. |
| Q34629092 | Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit. |
| Q40710316 | Synthesis of cholera toxin B subunit gene: cloning and expression of a functional 6XHis-tagged protein in Escherichia coli. |
| Q37628867 | The ABC of clinical and experimental adjuvants--a brief overview |
| Q37522842 | The B subunit of Escherichia coli heat-labile enterotoxin induces both caspase-dependent and -independent cell death pathways in CD8+ T cells |
| Q46801670 | The Escherichia coli heat-labile enterotoxin induces apoptosis of immature lymphocytes in vivo via a glucocorticoid-dependent pathway |
| Q40564857 | The cholera toxin B subunit directly costimulates antigen-primed CD4+ T cells ex vivo |
| Q47904800 | The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes |
| Q40504212 | The function of mitogen-activated protein kinase phosphatase-1 in peptidoglycan-stimulated macrophages |
| Q47105986 | Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa |
| Q39509403 | Tonsillar application of formalin-killed cells of Streptococcus sobrinus reduces experimental dental caries in rabbits. |
Search more.